Oncoproteomic profiling of AML: moving beyond genomics

Expert Rev Proteomics. 2022 Jul-Dec;19(7-12):283-287. doi: 10.1080/14789450.2023.2176757. Epub 2023 Feb 10.

Authors

Sunil K Joshi^{1

2}, Cristina E Tognon^{1

2}, Brian J Druker^{1

2}, Karin D Rodland^{1

3

4}

Affiliations

¹ Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
² Division of Hematology & Medical Oncology, Department of Medicine, Oregon Health & Science University, Portland, OR, USA.
³ Department of Cell, Developmental, and Cancer Biology, Oregon Health & Science University, Portland, OR, USA.
⁴ Pacific Northwest National Laboratory, Richland, WA, USA.

No abstract available

Keywords: AML; FLT3 inhibitor; drug resistance; leukemia; oncoproteomics; phosphoproteomics; proteogenomics.

Publication types

Editorial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Drug Resistance, Neoplasm*
Genomics
Humans
Leukemia, Myeloid, Acute* / genetics
Mutation
Protein Kinase Inhibitors / pharmacology

Substances

Protein Kinase Inhibitors

Grants and funding